Application of antiplatelet thrombolysin to preparation of medicine for treating retinal vein occlusion diseases

A retinal vein and anti-platelet technology, applied in the field of biomedicine, can solve problems such as not yet popularized, and achieve the effect of shortening vascular filling time, improving retinal vein occlusion, and improving the treatment of retinal vein occlusion

Pending Publication Date: 2021-04-09
ZHAOKE PHARMA HEFEI
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, it has been reported that intraretinal vein injection of thrombolytic drug tissue plasminogen activator has achieved good results, but it has not been popularized yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of antiplatelet thrombolysin to preparation of medicine for treating retinal vein occlusion diseases
  • Application of antiplatelet thrombolysin to preparation of medicine for treating retinal vein occlusion diseases
  • Application of antiplatelet thrombolysin to preparation of medicine for treating retinal vein occlusion diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1 Therapeutic effect of anti-platelet thrombolysin on photochemical method-induced retinal vein occlusion in rabbits

[0038] Twelve Dutch banded rabbits without obvious eye pigmentation were selected and randomly divided into 4 groups with 3 rabbits in each group. Group 1 was given normal saline, group 2 was vehicle control, group 3 was a low-dose anti-thrombolysin group (1.5 U / kg), and group 4 was a high-dose anti-thrombolysin group (6.0 U / kg ).

[0039] The antiplatelet thrombolysin used in the examples of the present invention consists of two peptide chains, α chain and β chain, the amino acid sequence of α chain is shown in SEQ ID NO.1, and the amino acid sequence of β chain is shown in SEQ ID NO.2.

[0040] On day 1, eyes of animals in groups 2-4 were dilated with tropicamide mydriatic agent. And the animals were anesthetized by combined intramuscular injection with ketamine (30-50 mg / kg) and thiarazine (3-8 mg / kg). After injecting Bengal red (50mg / kg) ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of antiplatelet thrombolysin to preparation of a medicine for treating retinal vein occlusion diseases, and is characterized in that the antiplatelet thrombolysin consists of two peptide chains, including an alpha chain and a beta chain, and the amino acid sequence of the alpha chain is as shown in SEQ ID NO.1, and the amino acid sequence of the beta chain is as shown in SEQ ID NO.2. According to the application of the antiplatelet thrombolysin to the medicine provided by the invention, photochemical method-induced retinal vein occlusion can be obviously improved, the choriocapillaris filling phase is shortened, and vascular recanalization is promoted, thus being beneficial to improvement and treatment of the retinal vein occlusion; and the antiplatelet thrombolysin has a good clinical application prospect.

Description

technical field [0001] The invention belongs to the field of biomedicine, in particular to the application of an antithrombolysin in the preparation of medicine for treating retinal vein occlusion disease. Background technique [0002] Retinal Vein Occlusion (RVO) is a common eye disease that can cause complications such as macular edema, vitreous hemorrhage, retinal detachment, and neovascular glaucoma, leading to vision loss and even blindness. The second blinding retinal vascular disease of the disease often occurs in people over 50 years old. According to the location of obstruction, RVO can be divided into 4 types: main trunk, half branch, branch and macular small branch block. Common venous occlusion occurs at or behind the cribriform plate. Half vein occlusion is due to the premature division of the vein into upper and lower branches in the optic disc, resulting in upper or lower half occlusion. Branch vein occlusion occurs on the retina, mostly at the first inters...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/36A61P9/10A61P27/02
CPCA61K38/36A61P9/10A61P27/02
Inventor 戴向荣李小羿刘斌
Owner ZHAOKE PHARMA HEFEI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap